Compare Hims and Hers Health Inc (HIMS) vs JBS N.V. Class A Common Shares (JBS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hims and Hers Health Inc vs JBS N.V. Class A Common Shares — how do they compare? Hims and Hers Health Inc trades at $27.58 (market cap $6.93B), while JBS N.V. Class A Common Shares trades at $13 (market cap $13.86B). The key difference: JBS N.V. Class A Common Shares is far larger — about 2× Hims and Hers Health Inc's market cap, and JBS N.V. Class A Common Shares pays a 10.38% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hims and Hers Health Inc for 21 Days and JBS N.V. Class A Common Shares for 0 Days on average.
| HIMS | JBS | |
|---|---|---|
Market Cap | $6.93B | $13.86B |
Volume | 9,771,956 | 4,980,049 |
Sector | Health | Consumer Staples |
52-Week High | $62.76 | $18.42 |
52-Week Low | $14.52 | $10.86 |
Typical Hold Time | 21 Days | 0 Days |
Enterprise Value | $7.64B | $34.83B |
Dividend Yield | — | 10.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HIMS trades at $29.71, down 3.04% today, amid ongoing securities class action lawsuits. The stock shows bullish technical signals with strong moving average support and key resistance at $32. Fundamentally, while revenue grew to $2.35B in 2025, the company posted a net loss of -$142M in 2026 with negative profit margins, though it maintains a solid gross margin of 68.4%.
The investment outlook is mixed: technical indicators suggest near-term upside potential toward the $32.17 consensus target, but fundamental weakness and legal overhangs pose significant risks. Analyst sentiment leans cautious with 65% hold ratings, reflecting concerns about profitability and regulatory challenges despite growth prospects.
JBS trades at $12.93, up 0.54% today, with a neutral technical signal and strong analyst buy consensus. The stock shows attractive valuation with a P/E of 12.08 and P/S of 0.47, though recent quarterly EPS misses and a declining profit margin to 1.22% in 2026 highlight earnings pressure. Recent news includes a proposal to acquire full control of Pilgrim's Pride and a joint venture in Southeast Asia, indicating strategic expansion.
The outlook is mixed: analyst targets suggest ~40% upside to $18.17, but risks include execution on acquisitions, margin compression, and volatile beef markets. Cash flow turned positive in 2026 projections, supporting growth initiatives, yet debt levels and competitive pressures warrant caution for investors seeking stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →About JBS N.V. Class A Common Shares
JBS N.V. is a protein-processing company producing beef, pork, poultry, lamb, fish, and plant-based products, headquartered in São Paulo and Amsterdam. It operates more than 250 production facilities across over 16 countries under brands including Friboi, Seara, Swift, and Pilgrim's, and is the majority shareholder of Pilgrim's Pride Corporation.
Read more on JBS →
